

Ref. No: 208230721  
From: Research  
Date: 23/07/21  
Subject: Treatment of spasticity

## REQUEST

We are analysing the treatment of spasticity and we would greatly appreciate it if you could please answer the following questions;

Q1. How many patients have been treated (for any condition) in the last 3 months with the following products:

- Baclofen
- Tizanidine
- Dantrolene sodium
- Diazepam
- Sativex
- Gabapentin
- Botox
- Dysport
- Xeomin

Q2. For patients treated for Multiple Sclerosis in the last 3 months, how many patients have been treated with the following products:

- Baclofen
- Tizanidine
- Dantrolene sodium
- Diazepam
- Sativex
- Gabapentin
- Botox
- Dysport
- Xeomin

Q3. For patients admitted for Stroke in the last 3 months, how many patients have been treated with the following products:

- Baclofen
- Tizanidine
- Dantrolene sodium

- Gabapentin
- Botox
- Dysport
- Xeomin

Q4. For patients admitted for Spinal or Brain Trauma in the last 3 months, how many patients have been treated with the following products:

- Baclofen
- Tizanidine
- Dantrolene sodium
- Gabapentin
- Botox
- Dysport
- Xeomin

Q5. Within your trust, how many patients have been treated (with any medication or procedure) in the past 12 months for the following conditions:

- Multiple Sclerosis
- Stroke
- Spinal or brain trauma

## RESPONSE

Q1. How many patients have been treated (for any condition) in the last 3 months (1<sup>st</sup> April 2021-30th June 2021) with the following products:

Baclofen	66
Tizanidine	*
Dantrolene sodium	*
Diazepam	255
Sativex	0
Gabapentin	188
Botox	483
Dysport	0
Xeomin	12

\* **Please note:** We are unable to provide precise figures when those figures refer to individuals in volumes of 5 or less due to the risk that individuals will be re-identified, as we are required to protect their identity under the General Data Protection Regulations & Data Protection Act 2018. In such circumstances sections 40(2) and (3) of the Freedom of Information Act apply. In this case, our view is that disclosure would breach the first data protection

principle. This states that personal data should be processed “lawfully, fairly and in a transparent manner”. It is the lawful aspect of this principle which, in our view, would be breached by disclosure. In such circumstances section 40 confers an absolute exemption on disclosure.

Q2. Pharmacy systems do not record the treatment/condition why a drug has been issued.

Q3. Pharmacy systems do not record the treatment/condition why a drug has been issued.

Q4. Pharmacy systems do not record the treatment/condition why a drug has been issued.

Q5. As previously agreed, the number of patients **diagnosed** from an inpatient stay (not treated) with the below for 01/07/2019 to 30/06/2021 are:

Multiple Sclerosis	174 patients
Stroke	1131 patients
Spinal or brain trauma	250 patients